Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

International Stem Cell (ISCO) Gross Profit (2016 - 2025)

International Stem Cell (ISCO) has disclosed Gross Profit for 16 consecutive years, with $1.9 million as the latest value for Q1 2025.

  • On a quarterly basis, Gross Profit rose 3.4% to $1.9 million in Q1 2025 year-over-year; TTM through Mar 2025 was $7.9 million, a 20.76% increase, with the full-year FY2024 number at $7.9 million, up 20.27% from a year prior.
  • Gross Profit was $1.9 million for Q1 2025 at International Stem Cell, down from $2.2 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $3.0 million in Q4 2023 to a low of $475000.0 in Q4 2022.
  • A 5-year average of $1.5 million and a median of $1.7 million in 2022 define the central range for Gross Profit.
  • Peak YoY movement for Gross Profit: skyrocketed 2538.1% in 2021, then crashed 57.13% in 2022.
  • International Stem Cell's Gross Profit stood at $1.1 million in 2021, then plummeted by 57.13% to $475000.0 in 2022, then skyrocketed by 523.37% to $3.0 million in 2023, then decreased by 27.12% to $2.2 million in 2024, then fell by 13.99% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Gross Profit are $1.9 million (Q1 2025), $2.2 million (Q4 2024), and $1.9 million (Q3 2024).